LivaNova PLC $LIVN Shares Purchased by Harbor Capital Advisors Inc.

Key Points

• Harbor Capital Advisors has increased its stake in LivaNova PLC by 20.3% during the second quarter, now holding approximately 0.19% of the company's stock valued at $4.6 million.
• LivaNova reported earnings of $1.05 per share for the last quarter, exceeding analyst estimates by $0.21, with revenue of $352.5 million, a 10.6% increase year-over-year.
• Analysts have recently upgraded LivaNova's rating to "strong-buy" and six analysts have rated the stock positively, with an average price target of $59.71.

Harbor Capital Advisors Inc. increased its stake in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 20.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 102,165 shares of the company's stock after acquiring an additional 17,252 shares during the quarter. Harbor Capital Advisors Inc. owned approximately 0.19% of LivaNova worth $4,599,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of the business. UMB Bank n.a. increased its position in LivaNova by 340.5% in the first quarter. UMB Bank n.a. now owns 837 shares of the company's stock worth $33,000 after buying an additional 647 shares in the last quarter. CWM LLC increased its holdings in shares of LivaNova by 52.3% in the 1st quarter. CWM LLC now owns 871 shares of the company's stock valued at $34,000 after acquiring an additional 299 shares during the period. Parallel Advisors LLC boosted its position in shares of LivaNova by 1,312.3% in the 2nd quarter. Parallel Advisors LLC now owns 1,031 shares of the company's stock worth $46,000 after purchasing an additional 958 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its position in LivaNova by 415.4% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 1,469 shares of the company's stock worth $58,000 after acquiring an additional 1,184 shares during the period. Finally, Strs Ohio purchased a new position in shares of LivaNova during the 1st quarter valued at about $130,000. Hedge funds and other institutional investors own 97.64% of the company's stock.

LivaNova Price Performance

LIVN stock traded down $0.91 during midday trading on Friday, hitting $55.00. The company's stock had a trading volume of 1,003,336 shares, compared to its average volume of 556,427. The company has a quick ratio of 1.09, a current ratio of 1.29 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $3.00 billion, a price-to-earnings ratio of -14.14 and a beta of 0.97. LivaNova PLC has a 12 month low of $32.48 and a 12 month high of $58.91. The company has a 50 day moving average of $50.74 and a two-hundred day moving average of $44.54.

LivaNova (NASDAQ:LIVN - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported $1.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.84 by $0.21. The firm had revenue of $352.50 million during the quarter, compared to analysts' expectations of $332.20 million. LivaNova had a positive return on equity of 14.57% and a negative net margin of 16.13%.The company's revenue for the quarter was up 10.6% compared to the same quarter last year. During the same period last year, the business posted $0.93 earnings per share. On average, analysts expect that LivaNova PLC will post 2.85 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on LIVN shares. Wall Street Zen upgraded LivaNova from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 9th. Barclays raised their price objective on shares of LivaNova from $55.00 to $58.00 and gave the company an "equal weight" rating in a research report on Thursday, August 21st. Finally, Needham & Company LLC reissued a "buy" rating and set a $64.00 price objective on shares of LivaNova in a research note on Wednesday, September 3rd. Six analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $59.71.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.